TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 1nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 1nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 1nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 2nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 3nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 3nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 3nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 3nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 3nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetIsoform PDE9A2 of High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (PDE9A2)(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMT: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetIsoform PDE9A2 of High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (PDE9A2)(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMT: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetIsoform PDE9A2 of High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (PDE9A2)(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMT: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetIsoform PDE9A2 of High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (PDE9A2)(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMT: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetIsoform PDE9A2 of High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (PDE9A2)(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 5nMT: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Boehringer Ingelheim International GmbH
US Patent
Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 6nMAssay Description:Cells expressing either endogenously the GlyT1 transporter like JAR cells (human placental choriocarcinoma cells; e.g. WO 2008/002583) or SK-N-MC cel...More data for this Ligand-Target Pair
![](/img/powered_by_small.gif)